However, among the articles selected based on the eligible criteria in this study, only two articles reported outcomes other than HCC by response to antiviral therapy: unchanged incidence of malignancy other than HCC by response to IFN44 and decreased progression to LC in patients without LC before IFN therapy by SVR to IFN45. Here, IFNA1 is linked to hepatocellular carcinoma.